{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:43:11Z","timestamp":1787586191760,"version":"build-2736575974"},"reference-count":159,"publisher":"e-Century Publishing Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/qfhj2430","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:50:47Z","timestamp":1746507047000},"page":"1494-1516","source":"Crossref","is-referenced-by-count":3,"title":["Targeting cancer-induced skeletal damage: a holistic approach to understanding pathophysiology, mechanisms, and management solutions"],"prefix":"10.62347","volume":"15","author":[{"given":"Xinyi","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Siegel RL, Giaquinto AN and Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74: 12-49.","DOI":"10.3322\/caac.21820"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12253-015-9975-y","article-title":"Pattern of tumour spread of common primary tumours as seen on magnetic resonance imaging","volume":"22","author":"Tarnoki","year":"2016","unstructured":"Tarnoki DL, Tarnoki AD, Ohlmann-Knafo S and Pickuth D. Pattern of tumour spread of common primary tumours as seen on magnetic resonance imaging. Pathol Oncol Res 2016; 22: 79-85.","journal-title":"Pathol Oncol Res"},{"key":"ref2","unstructured":"Ferguson JL and Turner SP. Bone cancer: diagnosis and treatment principles. Am Fam Physician 2018; 98: 205-213."},{"key":"ref3","unstructured":"Keil L. Bone tumors: primary bone cancers. FP Essent 2020; 493: 22-26."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"103340","DOI":"10.1016\/j.critrevonc.2021.103340","article-title":"Osteosarcoma, chondrosarcoma and Ewing sarcoma: clinical aspects, biomarker discovery and liquid biopsy","volume":"162","author":"Aran","year":"2021","unstructured":"Aran V, Devalle S, Meohas W, Heringer M, Cunha Caruso A, Pinheiro Aguiar D, Leite Duarte ME and Moura Neto V. Osteosarcoma, chondrosarcoma and Ewing sarcoma: clinical aspects, biomarker discovery and liquid biopsy. Crit Rev Oncol Hematol 2021; 162: 103340.","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s11914-024-00872-4","article-title":"The impact of non-bone metastatic cancer on musculoskeletal health","volume":"22","author":"Galiana-Melendez","year":"2024","unstructured":"Galiana-Melendez F and Huot JR. The impact of non-bone metastatic cancer on musculoskeletal health. Curr Osteoporos Rep 2024; 22: 318-329.","journal-title":"Curr Osteoporos Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11914-022-00741-y","article-title":"Muscle and bone defects in metastatic disease","volume":"20","author":"Pauk","year":"2022","unstructured":"Pauk M, Saito H, Hesse E and Taipaleenmäki H. Muscle and bone defects in metastatic disease. Curr Osteoporos Rep 2022; 20: 273-289.","journal-title":"Curr Osteoporos Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1177\/15353702211009213","article-title":"Role of myokines and osteokines in cancer cachexia","volume":"246","author":"Pin","year":"2021","unstructured":"Pin F, Bonewald LF and Bonetto A. Role of myokines and osteokines in cancer cachexia. Exp Biol Med (Maywood) 2021; 246: 2118-2127.","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jmir.2021.11.001","article-title":"Usefulness of (18)FDG-PET\/CT and MRI in an immunocompetent patient with fever of unknown origin and following diagnosis of skeletal tuberculosis: a case report","volume":"53","author":"Lavalle","year":"2022","unstructured":"Lavalle M, Belmonte G, Pallavicini F, Manfredi R and Minordi LM. Usefulness of (18)FDG-PET\/CT and MRI in an immunocompetent patient with fever of unknown origin and following diagnosis of skeletal tuberculosis: a case report. J Med Imaging Radiat Sci 2022; 53: 175-178.","journal-title":"J Med Imaging Radiat Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.3390\/diagnostics13142350","article-title":"Percutaneous CT-guided bone biopsies: indications, feasibility and diagnostic yield in the different skeletal sites-from the skull to the toe","volume":"13","author":"Spinnato","year":"2023","unstructured":"Spinnato P, Colangeli M, Rinaldi R and Ponti F. Percutaneous CT-guided bone biopsies: indications, feasibility and diagnostic yield in the different skeletal sites-from the skull to the toe. Diagnostics (Basel) 2023; 13: 2350.","journal-title":"Diagnostics (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Atkinson EG and Delgado-Calle J. The emerging role of osteocytes in cancer in bone. JBMR Plus 2019; 3: e10186.","DOI":"10.1002\/jbm4.10186"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"101809","DOI":"10.1016\/j.bonr.2024.101809","article-title":"Delineating the nexus between gut-intratumoral microbiome and osteo-immune system in bone metastases","volume":"23","author":"Kapoor","year":"2024","unstructured":"Kapoor S, Gupta M, Sapra L, Kaur T and Srivastava RK. Delineating the nexus between gut-intratumoral microbiome and osteo-immune system in bone metastases. Bone Rep 2024; 23: 101809.","journal-title":"Bone Rep"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"106775","DOI":"10.1016\/j.phrs.2023.106775","article-title":"Malignant function of nuclear factor-kappaB axis in prostate cancer: molecular interactions and regulation by non-coding RNAs","volume":"194","author":"Al-Rashidi RR","year":"2023","unstructured":"Al-Rashidi RR, Noraldeen SAM, Kareem AK, Mahmoud AK, Kadhum WR, Ramírez-Coronel AA, Iswanto AH, Obaid RF, Jalil AT, Nabavi N, Wang Y, Wang L and Mustafa YF. Malignant function of nuclear factor-kappaB axis in prostate cancer: molecular interactions and regulation by non-coding RNAs. Pharmacol Res 2023; 194: 106775.","journal-title":"Pharmacol Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/cells10061377","article-title":"Breast cancer with bone metastasis: molecular insights and clinical management","volume":"10","author":"Venetis","year":"2021","unstructured":"Venetis K, Piciotti R, Sajjadi E, Invernizzi M, Morganti S, Criscitiello C and Fusco N. Breast cancer with bone metastasis: molecular insights and clinical management. Cells 2021; 10: 1377.","journal-title":"Cells"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1067406","DOI":"10.3389\/fmolb.2022.1067406","article-title":"Insights into the role of long non-coding RNAs in DNA methylation mediated transcriptional regulation","volume":"9","author":"Yang","year":"2022","unstructured":"Yang Z, Xu F, Teschendorff AE, Zhao Y, Yao L, Li J and He Y. Insights into the role of long non-coding RNAs in DNA methylation mediated transcriptional regulation. Front Mol Biosci 2022; 9: 1067406.","journal-title":"Front Mol Biosci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.1158\/1078-0432.CCR-08-1572","article-title":"Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference","volume":"14","author":"Coleman","year":"2008","unstructured":"Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL and Weilbaecher KN. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 2008; 14: 6387-6395.","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10585-021-10076-0","article-title":"Molecular insights into the interplay between adiposity, breast cancer and bone metastasis","volume":"38","author":"Soni","year":"2021","unstructured":"Soni S, Torvund M and Mandal CC. Molecular insights into the interplay between adiposity, breast cancer and bone metastasis. Clin Exp Metastasis 2021; 38: 119-138.","journal-title":"Clin Exp Metastasis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.2174\/138161210793563536","article-title":"Targeted therapy options for treatment of bone metastases; beyond bisphosphonates","volume":"16","author":"JT","year":"2010","unstructured":"Buijs JT, Kuijpers CC and van der Pluijm G. Targeted therapy options for treatment of bone metastases; beyond bisphosphonates. Curr Pharm Des 2010; 16: 3015-3027.","journal-title":"Curr Pharm Des"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A, Van Poznak C, Aapro M and Jordan K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol 2020; 31: 1650-1663.","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"RE","year":"2020","unstructured":"Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R and Costa L. Bone metastases. Nat Rev Dis Primers 2020; 6: 83.","journal-title":"Nat Rev Dis Primers"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12094-022-02950-4","article-title":"The pro-tumorigenic responses in metastatic niches: an immunological perspective","volume":"25","author":"Mirzapour","year":"2023","unstructured":"Mirzapour MH, Heidari-Foroozan M, Razi S and Rezaei N. The pro-tumorigenic responses in metastatic niches: an immunological perspective. Clin Transl Oncol 2023; 25: 333-344.","journal-title":"Clin Transl Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1116783","DOI":"10.3389\/fonc.2023.1116783","article-title":"The metastatic niche formation: focus on extracellular vesicle-mediated dialogue between lung cancer cells and the microenvironment","volume":"13","author":"Pontis","year":"2023","unstructured":"Pontis F, Roz L, Fortunato O and Bertolini G. The metastatic niche formation: focus on extracellular vesicle-mediated dialogue between lung cancer cells and the microenvironment. Front Oncol 2023; 13: 1116783.","journal-title":"Front Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"598532","DOI":"10.3389\/fimmu.2020.598532","article-title":"The roles of stroma-derived chemokine in different stages of cancer metastases","volume":"11","author":"Hussain","year":"2020","unstructured":"Hussain S, Peng B, Cherian M, Song JW, Ahirwar DK and Ganju RK. The roles of stroma-derived chemokine in different stages of cancer metastases. Front Immunol 2020; 11: 598532.","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jconrel.2020.06.037","article-title":"Prognosis and targeting of pre-metastatic niche","volume":"325","author":"Zhou","year":"2020","unstructured":"Zhou Y, Han M and Gao J. Prognosis and targeting of pre-metastatic niche. J Control Release 2020; 325: 223-234.","journal-title":"J Control Release"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.addr.2015.11.017","article-title":"Heterogeneity of tumor cells in the bone microenvironment: mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer","volume":"99","author":"Futakuchi","year":"2016","unstructured":"Futakuchi M, Fukamachi K and Suzui M. Heterogeneity of tumor cells in the bone microenvironment: mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer. Adv Drug Deliv Rev 2016; 99: 206-211.","journal-title":"Adv Drug Deliv Rev"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10585-016-9798-6","article-title":"Bone microenvironment-mediated resistance of cancer cells to bisphosphonates and impact on bone osteocytes\/stem cells","volume":"33","author":"Alasmari","year":"2016","unstructured":"Alasmari A, Lin SC, Dibart S and Salih E. Bone microenvironment-mediated resistance of cancer cells to bisphosphonates and impact on bone osteocytes\/stem cells. Clin Exp Metastasis 2016; 33: 563-588.","journal-title":"Clin Exp Metastasis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"151422","DOI":"10.1016\/j.aanat.2019.151422","article-title":"The osteocyte: a multifunctional cell within the bone","volume":"227","author":"FGF","year":"2020","unstructured":"Tresguerres FGF, Torres J, López-Quiles J, Hernández G, Vega JA and Tresguerres IF. The osteocyte: a multifunctional cell within the bone. Ann Anat 2020; 227: 151422.","journal-title":"Ann Anat"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41419-019-1594-1","article-title":"IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis","volume":"10","author":"Liang","year":"2019","unstructured":"Liang M, Ma Q, Ding N, Luo F, Bai Y, Kang F, Gong X, Dong R, Dai J, Dai Q, Dou C and Dong S. IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis. Cell Death Dis 2019; 10: 353.","journal-title":"Cell Death Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bone.2010.07.015","article-title":"Advances in the biology of bone metastasis: how the skeleton affects tumor behavior","volume":"48","author":"Sterling","year":"2011","unstructured":"Sterling JA, Edwards JR, Martin TJ and Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 2011; 48: 6-15.","journal-title":"Bone"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10549-010-0889-9","article-title":"Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for osteopontin in affecting breast cancer cell migration","volume":"126","author":"Koro","year":"2011","unstructured":"Koro K, Parkin S, Pohorelic B, Yang AD, Narendran A, Egan C and Magliocco A. Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for osteopontin in affecting breast cancer cell migration. Breast Cancer Res Treat 2011; 126: 73-83.","journal-title":"Breast Cancer Res Treat"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1349-7006.2007.00690.x","article-title":"Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment","volume":"99","author":"Sato","year":"2008","unstructured":"Sato S, Futakuchi M, Ogawa K, Asamoto M, Nakao K, Asai K and Shirai T. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment. Cancer Sci 2008; 99: 316-323.","journal-title":"Cancer Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S and Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-495.","journal-title":"Lancet Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"KC","year":"2012","unstructured":"Fearon KC, Glass DJ and Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 2012; 16: 153-166.","journal-title":"Cell Metab"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.trecan.2018.10.001","article-title":"Cancer cachexia: more than skeletal muscle wasting","volume":"4","author":"Schmidt","year":"2018","unstructured":"Schmidt SF, Rohm M, Herzig S and Berriel Diaz M. Cancer cachexia: more than skeletal muscle wasting. Trends Cancer 2018; 4: 849-860.","journal-title":"Trends Cancer"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/nu15051193","article-title":"Pre-therapeutic sarcopenia among cancer patients: an up-to-date meta-analysis of prevalence and predictive value during cancer treatment","volume":"15","author":"AL","year":"2023","unstructured":"Couderc AL, Liuu E, Boudou-Rouquette P, Poisson J, Frelaut M, Montégut C, Mebarki S, Geiss R, ap Thomas Z, Noret A, Pierro M, Baldini C, Paillaud E and Pamoukdjian F. Pre-therapeutic sarcopenia among cancer patients: an up-to-date meta-analysis of prevalence and predictive value during cancer treatment. Nutrients 2023; 15: 1193.","journal-title":"Nutrients"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s00774-023-01444-9","article-title":"Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy","volume":"41","author":"Nisha","year":"2023","unstructured":"Nisha Y, Dubashi B, Bobby Z, Sahoo JP, Kayal S, Ananthakrishnan R, Reddy VB, L C and Ganesan P. Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy. J Bone Miner Metab 2023; 41: 682-692.","journal-title":"J Bone Miner Metab"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11657-022-01060-6","article-title":"Prognostic value of preoperative low bone mineral density in patients with digestive cancers: a systematic review and meta-analysis","volume":"17","author":"Watanabe","year":"2022","unstructured":"Watanabe J, Saitsu A, Miki A, Kotani K and Sata N. Prognostic value of preoperative low bone mineral density in patients with digestive cancers: a systematic review and meta-analysis. Arch Osteoporos 2022; 17: 33.","journal-title":"Arch Osteoporos"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/cam4.4416","article-title":"Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery","volume":"11","author":"Cameron","year":"2022","unstructured":"Cameron ME, Underwood PW, Williams IE, George TJ, Judge SM, Yarrow JF, Trevino JG and Judge AR. Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery. Cancer Med 2022; 11: 50-60.","journal-title":"Cancer Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00595-022-02550-3","article-title":"Osteosarcopenia predicts poor prognosis for patients with intrahepatic cholangiocarcinoma after hepatic resection","volume":"53","author":"Taniai","year":"2023","unstructured":"Taniai T, Haruki K, Yanagaki M, Igarashi Y, Furukawa K, Onda S, Yasuda J, Matsumoto M, Tsunematsu M and Ikegami T. Osteosarcopenia predicts poor prognosis for patients with intrahepatic cholangiocarcinoma after hepatic resection. Surg Today 2023; 53: 82-89.","journal-title":"Surg Today"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","unstructured":"Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S and Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999; 79: 1179-1181.","journal-title":"Br J Cancer"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00520-017-3962-7","article-title":"Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience","volume":"26","author":"Edwards","year":"2018","unstructured":"Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D and Murphy WA Jr. Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Support Care Cancer 2018; 26: 1561-1568.","journal-title":"Support Care Cancer"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41416-023-02353-4","article-title":"Fracture risk among patients with cancer compared to individuals without cancer: a population-based study","volume":"129","author":"Gong","year":"2023","unstructured":"Gong IY, Chan KKW, Lipscombe LL, Cheung MC and Mozessohn L. Fracture risk among patients with cancer compared to individuals without cancer: a population-based study. Br J Cancer 2023; 129: 665-671.","journal-title":"Br J Cancer"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3389\/fphys.2016.00679","article-title":"Differential bone loss in mouse models of colon cancer cachexia","volume":"7","author":"Bonetto","year":"2017","unstructured":"Bonetto A, Kays JK, Parker VA, Matthews RR, Barreto R, Puppa MJ, Kang KS, Carson JA, Guise TA, Mohammad KS, Robling AG, Couch ME, Koniaris LG and Zimmers TA. Differential bone loss in mouse models of colon cancer cachexia. Front Physiol 2017; 7: 679.","journal-title":"Front Physiol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"26041","DOI":"10.18632\/oncotarget.4667","article-title":"ZIP4 silencing improves bone loss in pancreatic cancer","volume":"6","author":"Zhang","year":"2015","unstructured":"Zhang Q, Sun X, Yang J, Ding H, LeBrun D, Ding K, Houchen CW, Postier RG, Ambrose CG, Li Z, Bi X and Li M. ZIP4 silencing improves bone loss in pancreatic cancer. Oncotarget 2015; 6: 26041-26051.","journal-title":"Oncotarget"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00223-013-9774-y","article-title":"Osteocyte-driven bone remodeling","volume":"94","author":"Bellido","year":"2014","unstructured":"Bellido T. Osteocyte-driven bone remodeling. Calcif Tissue Int 2014; 94: 25-34.","journal-title":"Calcif Tissue Int"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.clinimag.2015.09.016","article-title":"Application of quantitative computed tomography for assessment of trabecular bone mineral density, microarchitecture and mechanical property","volume":"40","author":"Mao","year":"2016","unstructured":"Mao SS, Li D, Luo Y, Syed YS and Budoff MJ. Application of quantitative computed tomography for assessment of trabecular bone mineral density, microarchitecture and mechanical property. Clin Imaging 2016; 40: 330-338.","journal-title":"Clin Imaging"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/pbc.22880","article-title":"Bone mineral density in newly diagnosed children with neuroblastoma","volume":"56","author":"Al-Tonbary","year":"2011","unstructured":"Al-Tonbary YA, El-Ziny MA, Elsharkawy AA, El-Hawary AK, El-Ashry R and Fouda AE. Bone mineral density in newly diagnosed children with neuroblastoma. Pediatr Blood Cancer 2011; 56: 202-205.","journal-title":"Pediatr Blood Cancer"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.21037\/atm-20-3751","article-title":"Computed tomography-measured bone mineral density as a surrogate marker of survival after resection of colorectal liver metastases","volume":"9","author":"Ikuta","year":"2021","unstructured":"Ikuta S, Aihara T, Nakajima T, Kasai M and Yamanaka N. Computed tomography-measured bone mineral density as a surrogate marker of survival after resection of colorectal liver metastases. Ann Transl Med 2021; 9: 21.","journal-title":"Ann Transl Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3904\/kjim.2023.386","article-title":"Cancer treatment-induced bone loss","volume":"39","author":"Choi","year":"2024","unstructured":"Choi YJ. Cancer treatment-induced bone loss. Korean J Intern Med 2024; 39: 731-745.","journal-title":"Korean J Intern Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.11138\/ccmbm\/2015.12.2.116","article-title":"Prevention and treatment of bone fragility in cancer patient","volume":"12","author":"Ottanelli","year":"2015","unstructured":"Ottanelli S. Prevention and treatment of bone fragility in cancer patient. Clin Cases Miner Bone Metab 2015; 12: 116-129.","journal-title":"Clin Cases Miner Bone Metab"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/14712598.2020.1814731","article-title":"Denosumab for cancer-related bone loss","volume":"20","author":"Dell&#x2019","year":"2020","unstructured":"Dell’Aquila E, Armento G, Iuliani M, Simonetti S, D’Onofrio L, Zeppola T, Madaudo C, Russano M, Citarella F, Ribelli G, Pantano F, Vincenzi B, Tonini G and Santini D. Denosumab for cancer-related bone loss. Expert Opin Biol Ther 2020; 20: 1261-1274.","journal-title":"Expert Opin Biol Ther"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1002\/ijc.27402","article-title":"The contrasting age-incidence patterns of bone tumours in teenagers and young adults: implications for aetiology","volume":"131","author":"Arora","year":"2012","unstructured":"Arora RS, Alston RD, Eden TO, Geraci M and Birch JM. The contrasting age-incidence patterns of bone tumours in teenagers and young adults: implications for aetiology. Int J Cancer 2012; 131: 1678-1685.","journal-title":"Int J Cancer"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Evola FR, Costarella L, Pavone V, Caff G, Cannavò L, Sessa A, Avondo S and Sessa G. Biomarkers of osteosarcoma, chondrosarcoma, and ewing sarcoma. Front Pharmacol 2017; 8: 150.","DOI":"10.3389\/fphar.2017.00150"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/BLO.0b013e318059b8c9","article-title":"Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma: national cancer data base report","volume":"459","author":"TA","year":"2007","unstructured":"Damron TA, Ward WG and Stewart A. Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma: national cancer data base report. Clin Orthop Relat Res 2007; 459: 40-47.","journal-title":"Clin Orthop Relat Res"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13569-020-00144-6","article-title":"Seeking international consensus on approaches to primary tumour treatment in Ewing sarcoma","volume":"10","author":"Gerrand","year":"2020","unstructured":"Gerrand C, Bate J, Seddon B, Dirksen U, Randall RL, van de Sande M, O’Donnell P, Tuckett J, Peake D, Jeys L, Saifuddin A, Grainger M and Whelan J. Seeking international consensus on approaches to primary tumour treatment in Ewing sarcoma. Clin Sarcoma Res 2020; 10: 21.","journal-title":"Clin Sarcoma Res"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Svensson E, Christiansen CF, Ulrichsen SP, Rørth MR and Sørensen HT. Survival after bone metastasis by primary cancer type: a Danish population-based cohort study. BMJ Open 2017; 7: e016022.","DOI":"10.1136\/bmjopen-2017-016022"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/pharmaceutics10040205","article-title":"Targeted nanomedicine to treat bone metastasis","volume":"10","author":"Adjei","year":"2018","unstructured":"Adjei IM, Temples MN, Brown SB and Sharma B. Targeted nanomedicine to treat bone metastasis. Pharmaceutics 2018; 10: 205.","journal-title":"Pharmaceutics"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","article-title":"Osteosarcoma","volume":"8","author":"Beird","year":"2022","unstructured":"Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ and Gorlick R. Osteosarcoma. Nat Rev Dis Primers 2022; 8: 77.","journal-title":"Nat Rev Dis Primers"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Mutsaers AJ and Walkley CR. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone 2014; 62: 56-63.","DOI":"10.1016\/j.bone.2014.02.003"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1111\/cas.15730","article-title":"Development of an osteosarcoma model with MYCN amplification and TP53 mutation in hiPS cell-derived neural crest cells","volume":"114","author":"Mukae","year":"2023","unstructured":"Mukae K, Takenobu H, Endo Y, Haruta M, Shi T, Satoh S, Ohira M, Funato M, Toguchida J, Osafune K, Nakahata T, Kanda H and Kamijo T. Development of an osteosarcoma model with MYCN amplification and TP53 mutation in hiPS cell-derived neural crest cells. Cancer Sci 2023; 114: 1898-1911.","journal-title":"Cancer Sci"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1158\/2159-8290.CD-17-1152","article-title":"Genome-informed targeted therapy for osteosarcoma","volume":"9","author":"Sayles","year":"2019","unstructured":"Sayles LC, Breese MR, Koehne AL, Leung SG, Lee AG, Liu HY, Spillinger A, Shah AT, Tanasa B, Straessler K, Hazard FK, Spunt SL, Marina N, Kim GE, Cho SJ, Avedian RS, Mohler DG, Kim MO, DuBois SG, Hawkins DS and Sweet-Cordero EA. Genome-informed targeted therapy for osteosarcoma. Cancer Discov 2019; 9: 46-63.","journal-title":"Cancer Discov"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.taap.2011.07.002","article-title":"Involvement of phorbol-12-myristate-13-acetate-induced protein 1 in goniothalamin-induced TP53-dependent and -independent apoptosis in hepatocellular carcinoma-derived cells","volume":"256","author":"Kuo","year":"2011","unstructured":"Kuo KK, Chen YL, Chen LR, Li CF, Lan YH, Chang FR, Wu YC and Shiue YL. Involvement of phorbol-12-myristate-13-acetate-induced protein 1 in goniothalamin-induced TP53-dependent and -independent apoptosis in hepatocellular carcinoma-derived cells. Toxicol Appl Pharmacol 2011; 256: 8-23.","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/modpathol.2012.97","article-title":"Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma","volume":"25","author":"WL","year":"2012","unstructured":"Wang WL, Patel NR, Caragea M, Hogendoorn PC, López-Terrada D, Hornick JL and Lazar AJ. Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma. Mod Pathol 2012; 25: 1378-1383.","journal-title":"Mod Pathol"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L and Goncalves F. Bone metastases: an overview. Oncol Rev 2017; 11: 321.","DOI":"10.4081\/oncol.2017.321"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.3390\/ijms20236047","article-title":"Bone pain in cancer patients: mechanisms and current treatment","volume":"20","author":"Zaj&#x105","year":"2019","unstructured":"Zajączkowska R, Kocot-Kępska M, Leppert W and Wordliczek J. Bone pain in cancer patients: mechanisms and current treatment. Int J Mol Sci 2019; 20: 6047.","journal-title":"Int J Mol Sci"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.3390\/ijms25052846","article-title":"Bridging the gap in understanding bone metastasis: a multifaceted perspective","volume":"25","author":"Elaasser","year":"2024","unstructured":"Elaasser B, Arakil N and Mohammad KS. Bridging the gap in understanding bone metastasis: a multifaceted perspective. Int J Mol Sci 2024; 25: 2846.","journal-title":"Int J Mol Sci"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3109\/07357907.2015.1047506","article-title":"Quality and outcomes of treatment of hypercalcemia of malignancy","volume":"33","author":"Wright","year":"2015","unstructured":"Wright JD, Tergas AI, Ananth CV, Burke WM, Hou JY, Chen L, Neugut AI, Richards CA and Hershman DL. Quality and outcomes of treatment of hypercalcemia of malignancy. Cancer Invest 2015; 33: 331-339.","journal-title":"Cancer Invest"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.21873\/anticanres.12817","article-title":"Metastatic spinal cord compression: unraveling the diagnostic and therapeutic challenges","volume":"38","author":"Boussios","year":"2018","unstructured":"Boussios S, Cooke D, Hayward C, Kanellos FS, Tsiouris AK, Chatziantoniou AA, Zakynthinakis-Kyriakou N and Karathanasi A. Metastatic spinal cord compression: unraveling the diagnostic and therapeutic challenges. Anticancer Res 2018; 38: 4987-4997.","journal-title":"Anticancer Res"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Barragán-Campos HM, Jiménez-Zarazúa O and Mondragón JD. Diagnosis and treatment options of spinal metastases. Rev Invest Clin 2015; 67: 140-157.","DOI":"10.1016\/S0034-8376(25)00233-5"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Łukaszewski B, Nazar J, Goch M, Łukaszewska M, Stępiński A and Jurczyk MU. Diagnostic methods for detection of bone metastases. Contemp Oncol (Pozn) 2017; 21: 98-103.","DOI":"10.5114\/wo.2017.68617"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12905-024-03234-5","article-title":"Relationships between nine neuropsychiatric disorders and cervical cancer: insights from genetics, causality and shared gene expression patterns","volume":"24","author":"Li","year":"2024","unstructured":"Li J, Qi J, Zhang J, Zhang Y and Huang X. Relationships between nine neuropsychiatric disorders and cervical cancer: insights from genetics, causality and shared gene expression patterns. BMC Womens Health 2024; 24: 394.","journal-title":"BMC Womens Health"},{"key":"ref71","unstructured":"Mess E, Ziembowska A, Staś J, Misiąg W and Chabowski M. Assessment of the emotional condition of women with cancer. Eur Rev Med Pharmacol Sci 2021; 25: 5429-5435."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/mco.0000000000000202","article-title":"Muscle strength: clinical and prognostic value of hand-grip dynamometry","volume":"18","author":"Bohannon","year":"2015","unstructured":"Bohannon RW. Muscle strength: clinical and prognostic value of hand-grip dynamometry. Curr Opin Clin Nutr Metab Care 2015; 18: 465-470.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref73","unstructured":"Voss EE, Goode RD, Cook JL and Crist BD. Survey of orthopaedic trauma providers: is MRI superior to CT scan for evaluating and preoperative planning for tibial plateau fractures? Mo Med 2022; 119: 261-265."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13312-019-1520-8","article-title":"Effect of vitamin D and calcium supplementation on bone mineral content in children with thalassemia","volume":"56","author":"Thiagarajan","year":"2019","unstructured":"Thiagarajan NR, Kumar CGD, Sahoo J and Krishnamurthy S. Effect of vitamin D and calcium supplementation on bone mineral content in children with thalassemia. Indian Pediatr 2019; 56: 307-310.","journal-title":"Indian Pediatr"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s41999-023-00819-5","article-title":"Exercise testing and training in frail older adults with an orthopedic impairment participating in a geriatric rehabilitation program: an international Delphi study","volume":"14","author":"Groen","year":"2023","unstructured":"Groen WG, Wattel EM, de Groot AJ, Meiland FJM, Hertogh CMPM and Gerrits KHL. Exercise testing and training in frail older adults with an orthopedic impairment participating in a geriatric rehabilitation program: an international Delphi study. Eur Geriatr Med 2023; 14: 985-997.","journal-title":"Eur Geriatr Med"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.path.2021.06.005","article-title":"Malignant cartilage-forming tumors","volume":"14","author":"Hameed","year":"2021","unstructured":"Hameed M. Malignant cartilage-forming tumors. Surg Pathol Clin 2021; 14: 605-617.","journal-title":"Surg Pathol Clin"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/modpathol.3800391","article-title":"Type II collagen as specific marker for mesenchymal chondrosarcomas compared to other small cell sarcomas of the skeleton","volume":"18","author":"M&#xFC","year":"2005","unstructured":"Müller S, Söder S, Oliveira AM, Inwards CY and Aigner T. Type II collagen as specific marker for mesenchymal chondrosarcomas compared to other small cell sarcomas of the skeleton. Mod Pathol 2005; 18: 1088-1094.","journal-title":"Mod Pathol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/00019606-200103000-00002","article-title":"Translocation (10;11;22)(p14;q24;q12) characterized by fluorescence in situ hybridization in a case of Ewing’s tumor","volume":"10","author":"Noguera","year":"2001","unstructured":"Noguera R, Pellín A, Navarro S, Carda C and Llombart-Bosch A. Translocation (10;11;22)(p14;q24;q12) characterized by fluorescence in situ hybridization in a case of Ewing’s tumor. Diagn Mol Pathol 2001; 10: 2-8.","journal-title":"Diagn Mol Pathol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1038\/onc.2013.441","article-title":"Context-dependent adaption of EpCAM expression in early systemic esophageal cancer","volume":"33","author":"Driemel","year":"2014","unstructured":"Driemel C, Kremling H, Schumacher S, Will D, Wolters J, Lindenlauf N, Mack B, Baldus SA, Hoya V, Pietsch JM, Panagiotidou P, Raba K, Vay C, Vallböhmer D, Harréus U, Knoefel WT, Stoecklein NH and Gires O. Context-dependent adaption of EpCAM expression in early systemic esophageal cancer. Oncogene 2014; 33: 4904-4915.","journal-title":"Oncogene"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"925807","DOI":"10.3389\/fonc.2022.925807","article-title":"Role of sphingolipids in multiple myeloma progression, drug resistance, and their potential as therapeutic targets","volume":"12","author":"DN","year":"2022","unstructured":"Petrusca DN, Lee KP and Galson DL. Role of sphingolipids in multiple myeloma progression, drug resistance, and their potential as therapeutic targets. Front Oncol 2022; 12: 925807.","journal-title":"Front Oncol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/jcp.24265","article-title":"Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro","volume":"228","author":"Zolochevska","year":"2013","unstructured":"Zolochevska O, Diaz-Quiñones AO, Ellis J and Figueiredo ML. Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro. J Cell Physiol 2013; 228: 1127-1136.","journal-title":"J Cell Physiol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2174\/156652412802480871","article-title":"Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment","volume":"12","author":"Li","year":"2012","unstructured":"Li Z, Xiao J, Wu X, Li W, Yang Z, Xie J, Xu L, Cai X, Lin Z, Guo W, Luo J and Liu M. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment. Curr Mol Med 2012; 12: 967-981.","journal-title":"Curr Mol Med"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jbspin.2017.05.006","article-title":"Pathophysiology of bone metastases from solid malignancies","volume":"84","author":"Cl&#xE9","year":"2017","unstructured":"Clézardin P. Pathophysiology of bone metastases from solid malignancies. Joint Bone Spine 2017; 84: 677-684.","journal-title":"Joint Bone Spine"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.cmet.2015.08.007","article-title":"PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer","volume":"22","author":"Dupuy","year":"2015","unstructured":"Dupuy F, Tabariès S, Andrzejewski S, Dong Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, Clemons M, Aguilar-Mahecha A, Basik M, Vincent EE, St-Pierre J, Jones RG and Siegel PM. PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metab 2015; 22: 577-589.","journal-title":"Cell Metab"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10585-019-09967-0","article-title":"Non-canonical roles for metabolic enzymes and intermediates in malignant progression and metastasis","volume":"36","author":"Williams","year":"2019","unstructured":"Williams D and Fingleton B. Non-canonical roles for metabolic enzymes and intermediates in malignant progression and metastasis. Clin Exp Metastasis 2019; 36: 211-224.","journal-title":"Clin Exp Metastasis"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3390\/cancers14020322","article-title":"Pathophysiological integration of metabolic reprogramming in breast cancer","volume":"14","author":"Corchado-Cobos R","year":"2022","unstructured":"Corchado-Cobos R, García-Sancha N, Mendiburu-Eliçabe M, Gómez-Vecino A, Jiménez-Navas A, Pérez-Baena MJ, Holgado-Madruga M, Mao JH, Cañueto J, Castillo-Lluva S and Pérez-Losada J. Pathophysiological integration of metabolic reprogramming in breast cancer. Cancers (Basel) 2022; 14: 322.","journal-title":"Cancers (Basel)"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.immuni.2015.09.001","article-title":"Metabolic reprogramming of immune cells in cancer progression","volume":"43","author":"Biswas","year":"2015","unstructured":"Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity 2015; 43: 435-449.","journal-title":"Immunity"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Trouvin AP and Goëb V. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 2010; 5: 345-354.","DOI":"10.2147\/CIA.S10153"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/bloodadvances.2017007310","article-title":"Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma","volume":"1","author":"Higgs","year":"2017","unstructured":"Higgs JT, Lee JH, Wang H, Ramani VC, Chanda D, Hardy CY, Sanderson RD and Ponnazhagan S. Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma. Blood Adv 2017; 1: 2375-2385.","journal-title":"Blood Adv"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1055\/a-1088-1215","article-title":"Thyroid hormone actions and bone remodeling - the role of the Wnt signaling pathway","volume":"128","author":"Lademann","year":"2020","unstructured":"Lademann F, Tsourdi E, Hofbauer LC and Rauner M. Thyroid hormone actions and bone remodeling - the role of the Wnt signaling pathway. Exp Clin Endocrinol Diabetes 2020; 128: 450-454.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"42084","DOI":"10.1074\/jbc.M112.377515","article-title":"miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells","volume":"287","author":"Hassan","year":"2012","unstructured":"Hassan MQ, Maeda Y, Taipaleenmaki H, Zhang W, Jafferji M, Gordon JA, Li Z, Croce CM, van Wijnen AJ, Stein JL, Stein GS and Lian JB. miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem 2012; 287: 42084-42092.","journal-title":"J Biol Chem"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s10020-024-00957-x","article-title":"Wnt\/β-catenin signaling pathway: proteins’ roles in osteoporosis and cancer diseases and the regulatory effects of natural compounds on osteoporosis","volume":"30","author":"Wang","year":"2024","unstructured":"Wang X, Qu Z, Zhao S, Luo L and Yan L. Wnt\/β-catenin signaling pathway: proteins’ roles in osteoporosis and cancer diseases and the regulatory effects of natural compounds on osteoporosis. Mol Med 2024; 30: 193.","journal-title":"Mol Med"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.3390\/cells12232695","article-title":"Effects of dickkopf-1 (DKK-1) on prostate cancer growth and bone metastasis","volume":"12","author":"Yuan","year":"2023","unstructured":"Yuan S, Hoggard NK, Kantake N, Hildreth BE 3rd and Rosol TJ. Effects of dickkopf-1 (DKK-1) on prostate cancer growth and bone metastasis. Cells 2023; 12: 2695.","journal-title":"Cells"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10266-015-0205-6","article-title":"Insulin-like growth factor-II regulates bone sialoprotein gene transcription","volume":"104","author":"Choe","year":"2016","unstructured":"Choe J, Sasaki Y, Zhou L, Takai H, Nakayama Y and Ogata Y. Insulin-like growth factor-II regulates bone sialoprotein gene transcription. Odontology 2016; 104: 271-281.","journal-title":"Odontology"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00776-004-0764-9","article-title":"Bone morphogenetic proteins in bone tumors","volume":"9","author":"Yoshikawa","year":"2004","unstructured":"Yoshikawa H, Nakase T, Myoui A and Ueda T. Bone morphogenetic proteins in bone tumors. J Orthop Sci 2004; 9: 334-340.","journal-title":"J Orthop Sci"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"572616","DOI":"10.3389\/fphar.2020.572616","article-title":"Paeonol suppresses proliferation and motility of non-small-cell lung cancer cells by disrupting STAT3\/NF-κB signaling","volume":"11","author":"Zhang","year":"2020","unstructured":"Zhang L, Chen WX, Li LL, Cao YZ, Geng YD, Feng XJ, Wang AY, Chen ZL, Lu Y and Shen AZ. Paeonol suppresses proliferation and motility of non-small-cell lung cancer cells by disrupting STAT3\/NF-κB signaling. Front Pharmacol 2020; 11: 572616.","journal-title":"Front Pharmacol"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2174\/1871520619666190206165215","article-title":"NF-κB-induced upregulation of miR-548as-3p increases invasion of NSCLC by targeting PTEN","volume":"19","author":"Akgun","year":"2019","unstructured":"Akgun S, Kucuksayan H, Ozes ON, Can O, Alikanoglu AS, Yildiz M and Akca H. NF-κB-induced upregulation of miR-548as-3p increases invasion of NSCLC by targeting PTEN. Anticancer Agents Med Chem 2019; 19: 1058-1068.","journal-title":"Anticancer Agents Med Chem"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"van Gassel RJJ, Baggerman MR and van de Poll MCG. Metabolic aspects of muscle wasting during critical illness. Curr Opin Clin Nutr Metab Care 2020; 23: 96-101.","DOI":"10.1097\/MCO.0000000000000628"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cre2.192","article-title":"The relationship between T-helper cell polarization and the RANKL\/OPG ratio in gingival tissues from chronic periodontitis patients","volume":"5","author":"CS","year":"2019","unstructured":"Bi CS, Sun LJ, Qu HL, Chen F, Tian BM and Chen FM. The relationship between T-helper cell polarization and the RANKL\/OPG ratio in gingival tissues from chronic periodontitis patients. Clin Exp Dent Res 2019; 5: 377-388.","journal-title":"Clin Exp Dent Res"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"López Roldán A, García Giménez JL and Alpiste Illueca F. Impact of periodontal treatment on the RANKL\/OPG ratio in crevicular fluid. PLoS One 2020; 15: e0227757.","DOI":"10.1371\/journal.pone.0227757"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11914-013-0171-2","article-title":"Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis","volume":"11","author":"Augustine","year":"2013","unstructured":"Augustine M and Horwitz MJ. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Curr Osteoporos Rep 2013; 11: 400-406.","journal-title":"Curr Osteoporos Rep"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1111\/febs.17224","article-title":"The role of interleukin-6 family cytokines in cancer cachexia","volume":"291","author":"Agca","year":"2024","unstructured":"Agca S and Kir S. The role of interleukin-6 family cytokines in cancer cachexia. FEBS J 2024; 291: 4009-4023.","journal-title":"FEBS J"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.21037\/atm-20-7269","article-title":"Inhibition of IL-6\/JAK\/STAT3 pathway rescues denervation-induced skeletal muscle atrophy","volume":"8","author":"Huang","year":"2020","unstructured":"Huang Z, Zhong L, Zhu J, Xu H, Ma W, Zhang L, Shen Y, Law BY, Ding F, Gu X and Sun H. Inhibition of IL-6\/JAK\/STAT3 pathway rescues denervation-induced skeletal muscle atrophy. Ann Transl Med 2020; 8: 1681.","journal-title":"Ann Transl Med"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Daou HN. Exercise as an anti-inflammatory therapy for cancer cachexia: a focus on interleukin-6 regulation. Am J Physiol Regul Integr Comp Physiol 2020; 318: R296-R310.","DOI":"10.1152\/ajpregu.00147.2019"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"597675","DOI":"10.3389\/fphys.2020.597675","article-title":"Inflammation and skeletal muscle wasting during cachexia","volume":"11","author":"Webster","year":"2020","unstructured":"Webster JM, Kempen LJAP, Hardy RS and Langen RCJ. Inflammation and skeletal muscle wasting during cachexia. Front Physiol 2020; 11: 597675.","journal-title":"Front Physiol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1002\/jcb.26490","article-title":"MiR 376c inhibits osteoblastogenesis by targeting Wnt3 and ARF-GEF-1 -facilitated augmentation of beta-catenin transactivation","volume":"119","author":"Kureel","year":"2018","unstructured":"Kureel J, John AA, Prakash R and Singh D. MiR 376c inhibits osteoblastogenesis by targeting Wnt3 and ARF-GEF-1 -facilitated augmentation of beta-catenin transactivation. J Cell Biochem 2018; 119: 3293-3303.","journal-title":"J Cell Biochem"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/jcb.21651","article-title":"Wnt signaling acts and is regulated in a human osteoblast differentiation dependent manner","volume":"104","author":"Eijken","year":"2008","unstructured":"Eijken M, Meijer IM, Westbroek I, Koedam M, Chiba H, Uitterlinden AG, Pols HA and van Leeuwen JP. Wnt signaling acts and is regulated in a human osteoblast differentiation dependent manner. J Cell Biochem 2008; 104: 568-579.","journal-title":"J Cell Biochem"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1538\/expanim.20-0046","article-title":"KLF5 regulates chicken skeletal muscle atrophy via the canonical Wnt\/β-catenin signaling pathway","volume":"69","author":"Zhang","year":"2020","unstructured":"Zhang DH, Yin HD, Li JJ, Wang Y, Yang CW, Jiang XS, Du HR and Liu YP. KLF5 regulates chicken skeletal muscle atrophy via the canonical Wnt\/β-catenin signaling pathway. Exp Anim 2020; 69: 430-440.","journal-title":"Exp Anim"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Rajasekaran MR, Kanoo S, Fu J, Nguyen ML, Bhargava V and Mittal RK. Age-related external anal sphincter muscle dysfunction and fibrosis: possible role of Wnt\/β-catenin signaling pathways. Am J Physiol Gastrointest Liver Physiol 2017; 313: G581-G588.","DOI":"10.1152\/ajpgi.00209.2017"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s13058-014-0408-8","article-title":"Nestin positively regulates the Wnt\/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells","volume":"16","author":"Zhao","year":"2014","unstructured":"Zhao Z, Lu P, Zhang H, Xu H, Gao N, Li M and Liu C. Nestin positively regulates the Wnt\/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells. Breast Cancer Res 2014; 16: 408.","journal-title":"Breast Cancer Res"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Lu Y, Ma J, Li Y, Huang J, Zhang S, Yin Z, Ren J, Huang K, Wu G, Yang K and Xu S. CDP138 silencing inhibits TGF-β\/Smad signaling to impair radioresistance and metastasis via GDF15 in lung cancer. Cell Death Dis 2017; 8: e3036.","DOI":"10.1038\/cddis.2017.434"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/onc.2015.95","article-title":"NAG-1\/GDF15 accumulates in the nucleus and modulates transcriptional regulation of the Smad pathway","volume":"35","author":"Min","year":"2016","unstructured":"Min KW, Liggett JL, Silva G, Wu WW, Wang R, Shen RF, Eling TE and Baek SJ. NAG-1\/GDF15 accumulates in the nucleus and modulates transcriptional regulation of the Smad pathway. Oncogene 2016; 35: 377-388.","journal-title":"Oncogene"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"152910","DOI":"10.1016\/j.phymed.2019.152910","article-title":"Longan fruit increase bone mineral density in zebrafish and ovariectomized rat by suppressing RANKL-induced osteoclast differentiation","volume":"59","author":"Son","year":"2019","unstructured":"Son Y, Lee EM, Lee DY, Lee JH and Oh S. Longan fruit increase bone mineral density in zebrafish and ovariectomized rat by suppressing RANKL-induced osteoclast differentiation. Phytomedicine 2019; 59: 152910.","journal-title":"Phytomedicine"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/bs.apcsb.2016.11.002","article-title":"NF-κB as a therapeutic target in inflammatory-associated bone diseases","volume":"107","author":"Lin","year":"2017","unstructured":"Lin TH, Pajarinen J, Lu L, Nabeshima A, Cordova LA, Yao Z and Goodman SB. NF-κB as a therapeutic target in inflammatory-associated bone diseases. Adv Protein Chem Struct Biol 2017; 107: 117-154.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"851394","DOI":"10.3389\/fnins.2022.851394","article-title":"The function of NF-Kappa B during epilepsy, a potential therapeutic target","volume":"16","author":"Cai","year":"2022","unstructured":"Cai M and Lin W. The function of NF-Kappa B during epilepsy, a potential therapeutic target. Front Neurosci 2022; 16: 851394.","journal-title":"Front Neurosci"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3892\/ol.2014.2127","article-title":"Homologous mesenchymal stem cells promote the emergence and growth of pulmonary metastases of the rat osteosarcoma cell line UMR-106","volume":"8","author":"Zhang","year":"2014","unstructured":"Zhang P, Dong L, Long H, Yang TT, Zhou Y, Fan QY and Ma BA. Homologous mesenchymal stem cells promote the emergence and growth of pulmonary metastases of the rat osteosarcoma cell line UMR-106. Oncol Lett 2014; 8: 127-132.","journal-title":"Oncol Lett"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1038\/s41388-023-02864-7","article-title":"Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype","volume":"42","author":"Vaghjiani","year":"2023","unstructured":"Vaghjiani VG, Cochrane CR, Jayasekara WSN, Chong WC, Szczepny A, Kumar B, Martelotto LG, McCaw A, Carey K, Kansara M, Thomas DM, Walkley C, Mudge S, Gough DJ, Downie PA, Peacock CD, Matsui W, Watkins DN and Cain JE. Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype. Oncogene 2023; 42: 3529-3541.","journal-title":"Oncogene"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/030089160909500307","article-title":"Prognostic implication of immunohistochemical Runx2 expression in osteosarcoma","volume":"95","author":"KY","year":"2009","unstructured":"Won KY, Park HR and Park YK. Prognostic implication of immunohistochemical Runx2 expression in osteosarcoma. Tumori 2009; 95: 311-316.","journal-title":"Tumori"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/ph14050421","article-title":"ICG-001, an Inhibitor of the β-Catenin and cAMP response element-binding protein dependent gene transcription, decreases proliferation but enhances migration of osteosarcoma cells","volume":"14","author":"Danieau","year":"2021","unstructured":"Danieau G, Morice S, Renault S, Brion R, Biteau K, Amiaud J, Cadé M, Heymann D, Lézot F, Verrecchia F, Rédini F and Brounais-Le Royer B. ICG-001, an Inhibitor of the β-Catenin and cAMP response element-binding protein dependent gene transcription, decreases proliferation but enhances migration of osteosarcoma cells. Pharmaceuticals (Basel) 2021; 14: 421.","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/path.2628","article-title":"Inactive Wnt\/beta-catenin pathway in conventional high-grade osteosarcoma","volume":"220","author":"Cai","year":"2010","unstructured":"Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G and Cleton-Jansen AM. Inactive Wnt\/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 2010; 220: 24-33.","journal-title":"J Pathol"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"110544","DOI":"10.1016\/j.biopha.2020.110544","article-title":"CCT128930 induces G1-phase arrest and apoptosis and synergistically enhances the anticancer efficiency of VS5584 in human osteosarcoma cells","volume":"130","author":"Sun","year":"2020","unstructured":"Sun JY, Hou YJ, Yin YB, Wang FZ, Yang MF, Zhang YY, Fan CD and Sun BL. CCT128930 induces G1-phase arrest and apoptosis and synergistically enhances the anticancer efficiency of VS5584 in human osteosarcoma cells. Biomed Pharmacother 2020; 130: 110544.","journal-title":"Biomed Pharmacother"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1080\/15384047.2015.1017155","article-title":"Activity of the novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma","volume":"16","author":"Zhu","year":"2015","unstructured":"Zhu YR, Min H, Fang JF, Zhou F, Deng XW and Zhang YQ. Activity of the novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma. Cancer Biol Ther 2015; 16: 602-609.","journal-title":"Cancer Biol Ther"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"215660","DOI":"10.1016\/j.canlet.2022.215660","article-title":"PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma","volume":"536","author":"Chen","year":"2022","unstructured":"Chen C, Guo Y, Huang Q, Wang B, Wang W, Niu J, Lou J, Xu J, Ren T, Huang Y and Guo W. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma. Cancer Lett 2022; 536: 215660.","journal-title":"Cancer Lett"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbrc.2018.12.078","article-title":"A new osteoclastogenesis pathway induced by cancer cells targeting osteoclast precursor cells","volume":"509","author":"Wada","year":"2019","unstructured":"Wada A, Tsuchiya M, Ozaki-Honda Y, Kayamori K, Sakamoto K, Yamaguchi A and Ikeda T. A new osteoclastogenesis pathway induced by cancer cells targeting osteoclast precursor cells. Biochem Biophys Res Commun 2019; 509: 108-113.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s10103-020-02993-5","article-title":"The effect of low-level laser radiation and doxycycline on the levels of osteoprotegerin and receptor activator of nuclear factor kappa-B ligand","volume":"35","author":"Farhad","year":"2020","unstructured":"Farhad SZ, Siadat A, Sadeghian N, Abrishamkar S, Khosraviani F, Khazaei P and Saberi-Demneh A. The effect of low-level laser radiation and doxycycline on the levels of osteoprotegerin and receptor activator of nuclear factor kappa-B ligand. Lasers Med Sci 2020; 35: 1975-1979.","journal-title":"Lasers Med Sci"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41413-022-00233-w","article-title":"A novel molecular classification method for osteosarcoma based on tumor cell differentiation trajectories","volume":"11","author":"Zhang","year":"2023","unstructured":"Zhang H, Wang T, Gong H, Jiang R, Zhou W, Sun H, Huang R, Wang Y, Wu Z, Xu W, Li Z, Huang Q, Cai X, Lin Z, Hu J, Jia Q, Ye C, Wei H and Xiao J. A novel molecular classification method for osteosarcoma based on tumor cell differentiation trajectories. Bone Res 2023; 11: 1.","journal-title":"Bone Res"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/cam4.2780","article-title":"Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer","volume":"9","author":"Ueno","year":"2020","unstructured":"Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B and Chasen BA. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med 2020; 9: 1025-1032.","journal-title":"Cancer Med"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1210\/js.2018-00425","article-title":"Mechanisms of osteoblastic bone metastasis in prostate cancer: role of prostatic acid phosphatase","volume":"3","author":"Quiroz-Munoz","year":"2019","unstructured":"Quiroz-Munoz M, Izadmehr S, Arumugam D, Wong B, Kirschenbaum A and Levine AC. Mechanisms of osteoblastic bone metastasis in prostate cancer: role of prostatic acid phosphatase. J Endocr Soc 2019; 3: 655-664.","journal-title":"J Endocr Soc"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/JES.0b013e3181f44f11","article-title":"Interleukin 6 as a key regulator of muscle mass during cachexia","volume":"38","author":"Carson","year":"2010","unstructured":"Carson JA and Baltgalvis KA. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev 2010; 38: 168-176.","journal-title":"Exerc Sport Sci Rev"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"1133828","DOI":"10.3389\/fonc.2023.1133828","article-title":"Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials","volume":"13","author":"Lu","year":"2023","unstructured":"Lu J, Hu D, Zhang Y, Ma C, Shen L and Shuai B. Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials. Front Oncol 2023; 13: 1133828.","journal-title":"Front Oncol"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3390\/medicina59101752","article-title":"The RANK-RANKL-OPG system: a multifaceted regulator of homeostasis, immunity, and cancer","volume":"59","author":"Leon-Oliva D","year":"2023","unstructured":"De Leon-Oliva D, Barrena-Blázquez S, Jiménez-Álvarez L, Fraile-Martinez O, García-Montero C, López-González L, Torres-Carranza D, García-Puente LM, Carranza ST, Álvarez-Mon MÁ, Álvarez-Mon M, Diaz R and Ortega MA. The RANK-RANKL-OPG system: a multifaceted regulator of homeostasis, immunity, and cancer. Medicina (Kaunas) 2023; 59: 1752.","journal-title":"Medicina (Kaunas)"},{"key":"ref132","doi-asserted-by":"publisher","unstructured":"Hesse E, Schröder S, Brandt D, Pamperin J, Saito H and Taipaleenmäki H. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight 2019; 5: e125543.","DOI":"10.1172\/jci.insight.125543"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"11399","DOI":"10.1038\/s41598-017-11913-7","article-title":"Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer","volume":"7","author":"Zhu","year":"2017","unstructured":"Zhu M, Liu C, Li S, Zhang S, Yao Q and Song Q. Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer. Sci Rep 2017; 7: 11399.","journal-title":"Sci Rep"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/jcsm.12441","article-title":"Tumour-derived transforming growth factor-β signalling contributes to fibrosis in patients with cancer cachexia","volume":"10","author":"JDCC","year":"2019","unstructured":"Lima JDCC, Simoes E, de Castro G, Morais MRPT, de Matos-Neto EM, Alves MJ, Pinto NI, Figueredo RG, Zorn TMT, Felipe-Silva AS, Tokeshi F, Otoch JP, Alcantara P, Cabral FJ, Ferro ES, Laviano A and Seelaender M. Tumour-derived transforming growth factor-β signalling contributes to fibrosis in patients with cancer cachexia. J Cachexia Sarcopenia Muscle 2019; 10: 1045-1059.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref135","doi-asserted-by":"publisher","unstructured":"Dasgupta A, Gibbard DF, Schmitt RE, Arneson-Wissink PC, Ducharme AM, Bruinsma ES, Hawse JR, Jatoi A and Doles JD. A TGF-β\/KLF10 signaling axis regulates atrophy-associated genes to induce muscle wasting in pancreatic cancer. Proc Natl Acad Sci U S A 2023; 120: e2215095120.","DOI":"10.1073\/pnas.2215095120"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40360-024-00770-6","article-title":"Comparative analysis of adverse events associated with CDK4\/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study","volume":"25","author":"Lin","year":"2024","unstructured":"Lin W, Zeng Y, Weng L, Yang J and Zhuang W. Comparative analysis of adverse events associated with CDK4\/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study. BMC Pharmacol Toxicol 2024; 25: 47.","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00280-021-04363-6","article-title":"Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4\/6-Cyclin D-Rb pathway","volume":"89","author":"Wang","year":"2022","unstructured":"Wang D and Bao H. Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4\/6-Cyclin D-Rb pathway. Cancer Chemother Pharmacol 2022; 89: 31-40.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1039\/D3MD00004D","article-title":"Research progress of anticancer drugs targeting CDK12","volume":"14","author":"Yan","year":"2023","unstructured":"Yan Z, Du Y, Zhang H, Zheng Y, Lv H, Dong N and He F. Research progress of anticancer drugs targeting CDK12. RSC Med Chem 2023; 14: 1629-1644.","journal-title":"RSC Med Chem"},{"key":"ref139","doi-asserted-by":"publisher","unstructured":"Chen B and Liu J. Development of CDK12 as a cancer therapeutic target and related inhibitors. Curr Cancer Drug Targets 2024; [Epub ahead of print].","DOI":"10.2174\/0115680096307629240611104728"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"15936","DOI":"10.1038\/ncomms15936","article-title":"Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma","volume":"8","author":"Behjati","year":"2017","unstructured":"Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I, Cooke SL, Davies H, Mifsud W, Lidgren M, Martin S, Latimer C, Maddison M, Butler AP, Teague JW, Pillay N, Shlien A, McDermott U, Futreal PA, Baumhoer D, Zaikova O, Bjerkehagen B, Myklebost O, Amary MF, Tirabosco R, Van Loo P, Stratton MR, Flanagan AM and Campbell PJ. Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nat Commun 2017; 8: 15936.","journal-title":"Nat Commun"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00264-019-04332-y","article-title":"Survival analysis of elderly patients with osteosarcoma","volume":"43","author":"Imura","year":"2019","unstructured":"Imura Y, Takenaka S, Kakunaga S, Nakai T, Wakamatsu T, Outani H, Tanaka T, Tamiya H, Oshima K, Hamada K, Naka N, Araki N, Kudawara I, Ueda T and Yoshikawa H. Survival analysis of elderly patients with osteosarcoma. Int Orthop 2019; 43: 1741-1747.","journal-title":"Int Orthop"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1002\/hed.26817","article-title":"Head and neck osteosarcomas: analysis of treatment trends and survival outcomes in the United States (2004-2016)","volume":"43","author":"Shim","year":"2021","unstructured":"Shim T, Chillakuru Y, Darwish C, Chalif E, Strum D, Benito DA, Mulcahy CF and Monfared A. Head and neck osteosarcomas: analysis of treatment trends and survival outcomes in the United States (2004-2016). Head Neck 2021; 43: 3294-3305.","journal-title":"Head Neck"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/jso.1142","article-title":"Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection","volume":"78","author":"Berend","year":"2001","unstructured":"Berend KR, Pietrobon R, Moore JO, Dibernardo L, Harrelson JM and Scully SP. Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. J Surg Oncol 2001; 78: 162-170.","journal-title":"J Surg Oncol"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"31","DOI":"10.21037\/atm-20-4764","article-title":"Primary tumor surgery improves survival of cancer patients with synchronous solitary bone metastasis: a large population-based study","volume":"9","author":"Wu","year":"2021","unstructured":"Wu W, Zhang H, Fang Z and Li F. Primary tumor surgery improves survival of cancer patients with synchronous solitary bone metastasis: a large population-based study. Ann Transl Med 2021; 9: 31.","journal-title":"Ann Transl Med"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/b109924_4","article-title":"Late effects of chemotherapy","volume":"150","author":"Gururangan","year":"2009","unstructured":"Gururangan S. Late effects of chemotherapy. Cancer Treat Res 2009; 150: 43-65.","journal-title":"Cancer Treat Res"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1080\/02648725.2023.2200302","article-title":"Analysis of the effect of mini-nutrition nursing plus Baduanjin rehabilitation exercise on fracture healing, mobility and nutritional status of elderly patients with vertebral or hip fractures","volume":"40","author":"Wang","year":"2024","unstructured":"Wang L and Zhang G. Analysis of the effect of mini-nutrition nursing plus Baduanjin rehabilitation exercise on fracture healing, mobility and nutritional status of elderly patients with vertebral or hip fractures. Biotechnol Genet Eng Rev 2024; 40: 2508-2519.","journal-title":"Biotechnol Genet Eng Rev"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3389\/fonc.2019.01146","article-title":"Their role in tumorigenesis, metastasis, prognosis and therapy","volume":"9","author":"MT","year":"2019","unstructured":"Masucci MT, Minopoli M and Carriero MV. Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol 2019; 9: 1146.","journal-title":"Front Oncol"},{"key":"ref148","doi-asserted-by":"publisher","unstructured":"Zinnen SP, Karpeisky A, Von Hoff DD, Plekhova L and Alexandrov A. First-in-human phase I study of MBC-11, a novel bone-targeted cytarabine-etidronate conjugate in patients with cancer-induced bone disease. Oncologist 2019; 24: 303-e102.","DOI":"10.1634\/theoncologist.2018-0707"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.18632\/oncotarget.27801","article-title":"Phase I dose escalation study of 12b80 (hydroxybisphosphonate linked doxorubicin) in naturally occurring osteosarcoma","volume":"11","author":"Boy&#xE9","year":"2020","unstructured":"Boyé P, David E, Serres F, Pascal Q, Floch F, Geeraert K, Coste V, Marescaux L, Cagnol S, Goujon JY, Egorov M, Le Bot R and Tierny D. Phase I dose escalation study of 12b80 (hydroxybisphosphonate linked doxorubicin) in naturally occurring osteosarcoma. Oncotarget 2020; 11: 4281-4292.","journal-title":"Oncotarget"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1021\/acs.bioconjchem.9b00210","article-title":"12b80 - hydroxybisphosphonate linked doxorubicin: bone targeted strategy for treatment of osteosarcoma","volume":"30","author":"David","year":"2019","unstructured":"David E, Cagnol S, Goujon JY, Egorov M, Taurelle J, Benesteau C, Morandeau L, Moal C, Sicard M, Pairel S, Heymann D, Redini F, Gouin F and Le Bot R. 12b80 - hydroxybisphosphonate linked doxorubicin: bone targeted strategy for treatment of osteosarcoma. Bioconjug Chem 2019; 30: 1665-1676.","journal-title":"Bioconjug Chem"},{"key":"ref151","unstructured":"Belfiore G, Tedeschi E, Ronza FM, Belfiore MP, Della Volpe T, Zeppetella G and Rotondo A. Radiofrequency ablation of bone metastases induces long-lasting palliation in patients with untreatable cancer. Singapore Med J 2008; 49: 565-570."},{"key":"ref152","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1517\/13543780903048929","article-title":"RANKL inhibition for the management of patients with benign metabolic bone disorders","volume":"18","author":"Anastasilakis","year":"2009","unstructured":"Anastasilakis AD, Toulis KA, Polyzos SA and Terpos E. RANKL inhibition for the management of patients with benign metabolic bone disorders. Expert Opin Investig Drugs 2009; 18: 1085-1102.","journal-title":"Expert Opin Investig Drugs"},{"key":"ref153","unstructured":"Gujral A, Burton DW, Terkeltaub R and Deftos LJ. Parathyroid hormone-related protein induces interleukin 8 production by prostate cancer cells via a novel intracrine mechanism not mediated by its classical nuclear localization sequence. Cancer Res 2001; 61: 2282-2288."},{"key":"ref154","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s00223-006-0099-y","article-title":"Transient exposure to PTHrP (107-139) exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro","volume":"79","author":"Gort&#xE1","year":"2006","unstructured":"de Gortázar AR, Alonso V, Alvarez-Arroyo MV and Esbrit P. Transient exposure to PTHrP (107-139) exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro. Calcif Tissue Int 2006; 79: 360-369.","journal-title":"Calcif Tissue Int"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.maturitas.2014.04.016","article-title":"Anti-sclerostin antibodies: utility in treatment of osteoporosis","volume":"78","author":"Clarke","year":"2014","unstructured":"Clarke BL. Anti-sclerostin antibodies: utility in treatment of osteoporosis. Maturitas 2014; 78: 199-204.","journal-title":"Maturitas"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1615\/CritRevOncog.v17.i2.30","article-title":"Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling","volume":"17","author":"Boone","year":"2012","unstructured":"Boone DN and Lee AV. Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog 2012; 17: 161-173.","journal-title":"Crit Rev Oncog"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/01.blo.0000229315.58878.c1","article-title":"Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma","volume":"450","author":"Shaheen","year":"2006","unstructured":"Shaheen M, Deheshi BM, Riad S, Werier J, Holt GE, Ferguson PC and Wunder JS. Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma. Clin Orthop Relat Res 2006; 450: 76-81.","journal-title":"Clin Orthop Relat Res"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bone.2010.03.006","article-title":"A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites","volume":"47","author":"MM","year":"2010","unstructured":"Reinholz MM, Zinnen SP, Dueck AC, Dingli D, Reinholz GG, Jonart LA, Kitzmann KA, Bruzek AK, Negron V, Abdalla AK, Arendt BK, Croatt AJ, Sanchez-Perez L, Sebesta DP, Lönnberg H, Yoneda T, Nath KA, Jelinek DF, Russell SJ, Ingle JN, Spelsberg TC, Dixon HB, Karpeisky A and Lingle WL. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone 2010; 47: 12-22.","journal-title":"Bone"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/4\/ajcr0162638.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:00:14Z","timestamp":1766023214000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/4\/ajcr0162638.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":159,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/qfhj2430","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}